Upstream Bioprocessing 2021

Enabling development of commercial-ready lentiviral vector manufacturing processes using stable producer cell lines

Cell & Gene Therapy Insights 2021; 7(9), 981–993


Published: 22 September 2021
Peter Archibald, Ph.D, Anthony Shillings

The manufacture of lentiviral vectors (LVVs) is currently a bottleneck for the development of cell and gene therapies. Typical upstream and downstream processes are often low-yielding, unscalable, involve many manual operations, and are poorly characterized. In this article, we describe the potential that LVV stable producer cell lines offer when used in upstream processes based upon suspension culture systems, and the implications that this can have on downstream unit operations. We also describe potential areas for innovation in order to develop LVV manufacturing processes suitable for commercial supply of potentially transformative cell and gene therapy medicines.